Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction - PubMed (original) (raw)
Clinical Trial
Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction
Takahiko Iuchi et al. Circ Res. 2003.
Abstract
Glucocorticoid (GC) excess often elicits serious adverse effects on the vascular system, such as hypertension and atherosclerosis, and effective prophylaxis for these complications is limited. We sought to reveal the mechanism underlying GC-induced vascular complications. Responses in forearm blood flow to reactive hyperemia in 20 GC-treated patients were significantly decreased to 43+/-8.9% (mean+/-SEM) from the values obtained before GC therapy (130+/-14%). An administration of vitamin C almost normalized blood flow responses. In human umbilical vein endothelial cells (HUVECs), production of hydrogen peroxide was increased up to 166.5+/-3.3% of control values by 10(-7) mol/L dexamethasone (DEX) treatment (P<0.01). Concomitant with DEX-induced hydrogen peroxide production, intracellular amounts of peroxynitrite significantly increased and those of nitric oxide (NO) decreased, respectively (P<0.01). Immunoblotting analysis using anti-nitrotyrosine antibody showed that peroxynitrite formation was increased in DEX-treated HUVECs. Using inhibitors against metabolic pathways for generation of reactive oxygen species (ROS), we identified that the major production sources of ROS by DEX treatment were mitochondrial electron transport chain, NAD(P)H oxidase, and xanthine oxidase. These findings suggest that GC excess causes overproduction of ROS and thereby perturbs NO availability in the vascular endothelium, leading to vascular complications in patients with GC excess.
Similar articles
- Role of redox signaling and poly (adenosine diphosphate-ribose) polymerase activation in vascular smooth muscle cell growth inhibition by nitric oxide and peroxynitrite.
Huang J, Lin SC, Nadershahi A, Watts SW, Sarkar R. Huang J, et al. J Vasc Surg. 2008 Mar;47(3):599-607. doi: 10.1016/j.jvs.2007.11.006. J Vasc Surg. 2008. PMID: 18295111 - Role of TNF-alpha-induced reactive oxygen species in endothelial dysfunction during reperfusion injury.
Gao X, Zhang H, Belmadani S, Wu J, Xu X, Elford H, Potter BJ, Zhang C. Gao X, et al. Am J Physiol Heart Circ Physiol. 2008 Dec;295(6):H2242-9. doi: 10.1152/ajpheart.00587.2008. Epub 2008 Oct 10. Am J Physiol Heart Circ Physiol. 2008. PMID: 18849334 Free PMC article. - Role of increased production of superoxide anions by NAD(P)H oxidase and xanthine oxidase in prolonged endotoxemia.
Brandes RP, Koddenberg G, Gwinner W, Kim Dy, Kruse HJ, Busse R, Mügge A. Brandes RP, et al. Hypertension. 1999 May;33(5):1243-9. doi: 10.1161/01.hyp.33.5.1243. Hypertension. 1999. PMID: 10334819 - Endothelial NADH/NADPH-dependent enzymatic sources of superoxide production: relationship to endothelial dysfunction.
Kalinowski L, Malinski T. Kalinowski L, et al. Acta Biochim Pol. 2004;51(2):459-69. Acta Biochim Pol. 2004. PMID: 15218542 Review. - NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities.
Paravicini TM, Touyz RM. Paravicini TM, et al. Diabetes Care. 2008 Feb;31 Suppl 2:S170-80. doi: 10.2337/dc08-s247. Diabetes Care. 2008. PMID: 18227481 Review.
Cited by
- Prenatal glucocorticoids exposure and adverse cardiovascular effects in offspring.
Zhao C, He L, Li L, Deng F, Zhang M, Wang C, Qiu J, Gao Q. Zhao C, et al. Front Endocrinol (Lausanne). 2024 Sep 16;15:1430334. doi: 10.3389/fendo.2024.1430334. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39351527 Free PMC article. Review. - Genetically predicted hypothyroidism, thyroid hormone treatment, and the risk of cardiovascular diseases: a mendelian randomization study.
Zhang S, Yu H, Zhao Y, Gong A, Guan C, Chen S, Xiao B, Lu J. Zhang S, et al. BMC Cardiovasc Disord. 2024 Sep 10;24(1):479. doi: 10.1186/s12872-024-04132-2. BMC Cardiovasc Disord. 2024. PMID: 39256710 Free PMC article. - Cycloastragenol prevents bone loss via inhibiting osteoclast activity in glucocorticoid-induced osteonecrosis of the femoral head: An in vivo study.
Wang G, Ma C, Mo L, Chen J, Yuan J, Xu J, He W. Wang G, et al. J Orthop Translat. 2024 Mar 23;45:178-187. doi: 10.1016/j.jot.2024.01.009. eCollection 2024 Mar. J Orthop Translat. 2024. PMID: 38549807 Free PMC article. - Excess glucocorticoids inhibit murine bone turnover via modulating the immunometabolism of the skeletal microenvironment.
Li X, Liang T, Dai B, Chang L, Zhang Y, Hu S, Guo J, Xu S, Zheng L, Yao H, Lian H, Nie Y, Li Y, He X, Yao Z, Tong W, Wang X, Chow DHK, Xu J, Qin L. Li X, et al. J Clin Invest. 2024 Mar 21;134(10):e166795. doi: 10.1172/JCI166795. J Clin Invest. 2024. PMID: 38512413 Free PMC article. - Cellular senescence is associated with osteonecrosis of the femoral head while mesenchymal stem cell conditioned medium inhibits bone collapse.
Okamoto M, Nakashima H, Sakai K, Takegami Y, Osawa Y, Watanabe J, Ito S, Hibi H, Imagama S. Okamoto M, et al. Sci Rep. 2024 Feb 9;14(1):3329. doi: 10.1038/s41598-024-53400-w. Sci Rep. 2024. PMID: 38337011 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous